Scripps Florida Selects GenoLogics Platform for Proteomics and Systems Biology Research
News Feb 14, 2006
GenoLogics Life Sciences Software Inc. has announced that Scripps Florida, a division of The Scripps Research Institute, has selected GenoLogics solutions for its lab and scientific data management system for proteomics and systems biology research.
Scripps Florida has a focus on biomedical research, technology development and drug design. Several core facilities are being set up to support research including proteomics, cytometry, high throughput screening, micro arrays and others.
The proteomics program at Scripps Florida is focusing on developing and applying advanced technologies in mass spectrometry-based proteomics to answer questions on how proteins are modified by cells in certain diseases.
Scripps Florida is building a foundation system that will serve all the core facilities for their data management and analysis needs.
According to Dr. Nick Tsinoremas, Senior Director and Head of Informatics at Scripps Florida, "Our scientists want data analysis tools but to get this to work, we need the data collected and stored in a consistent and managed way."
"From the bioinformatics perspective, we are looking for a means to acquire data in context and have one central place to uniformly access the data and not have to develop integration points between everything."
"We also want a system that can cross over with other discipline areas, such as genotyping, micro array and gene expression. GenoLogics solutions can meet these needs."
"The GenoLogics open integrating platform is scalable and flexible and it fits with our overall informatics infrastructure, future software development and rapid expansion plans," says Chris Mader, Chief Software Engineer at Scripps Florida.
"The Java based architecture is a perfect fit for us and allows us to easily integrate our own in-house developed software tools, open source tools and other software."
Dr. Jennifer Busby, Associate Lab Director for the proteomics program at Scripps Florida comments, "We really like the GenoLogics Proteus solution for our lab and data management."
"It takes no effort to configure our varied workflows and I don’t even have to think about the system - it just works in the background and I can concentrate on the real science and not worry about losing or keeping track of data."
"We needed a fast implementation and to be operational quickly to fit in with the timing of our expansion and to service the needs of our scientists. The proteomics group is already producing data so the need for data management is already there," said Chris Mader.
Michael Ball, CEO of GenoLogics says, "We place great importance on developing a collaborative relationship with our customers and we look forward to partnering with Scripps for future development of products and tools that meet their needs."
"We really value having Scripps Florida as our customer and we are excited to contribute to increasing the effectiveness of the important research work they are doing."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE